Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORT NASDAQ:BBNX NYSE:INSP NASDAQ:PLSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$25.36-28.4%$36.50$19.16▼$48.25$1.72B1.41340,683 shs5.14 million shsBBNXBeta Bionics$9.65-8.1%$10.97$8.80▼$32.71$467.90M3.291.14 million shs755,376 shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.31B0.831.18 million shs971,765 shsPLSEPulse Biosciences$19.08-2.6%$20.85$12.56▼$26.30$1.34B1.63248,413 shs201,687 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion0.00%-1.14%-2.07%-10.41%+24.85%BBNXBeta Bionics0.00%+2.94%+7.25%-19.72%-26.93%INSPInspire Medical Systems0.00%-18.75%-14.75%-30.86%-71.01%PLSEPulse Biosciences0.00%-7.46%+2.78%-5.59%+17.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$25.36-28.4%$36.50$19.16▼$48.25$1.72B1.41340,683 shs5.14 million shsBBNXBeta Bionics$9.65-8.1%$10.97$8.80▼$32.71$467.90M3.291.14 million shs755,376 shsINSPInspire Medical Systems$44.28-2.8%$56.01$43.99▼$161.88$1.31B0.831.18 million shs971,765 shsPLSEPulse Biosciences$19.08-2.6%$20.85$12.56▼$26.30$1.34B1.63248,413 shs201,687 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion0.00%-1.14%-2.07%-10.41%+24.85%BBNXBeta Bionics0.00%+2.94%+7.25%-19.72%-26.93%INSPInspire Medical Systems0.00%-18.75%-14.75%-30.86%-71.01%PLSEPulse Biosciences0.00%-7.46%+2.78%-5.59%+17.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 2.88Moderate Buy$47.8388.59% UpsideBBNXBeta Bionics 2.67Moderate Buy$22.00127.98% UpsideINSPInspire Medical Systems 2.15Hold$85.0091.95% UpsidePLSEPulse Biosciences 2.33Hold$30.0057.23% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, AORT, INSP, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026AORTArtivion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$53.00 ➝ $48.005/8/2026AORTArtivion Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $44.005/7/2026INSPInspire Medical Systems OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform5/6/2026INSPInspire Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/5/2026INSPInspire Medical Systems Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$56.00 ➝ $45.005/5/2026INSPInspire Medical Systems EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.005/5/2026INSPInspire Medical Systems Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$85.00 ➝ $55.005/5/2026INSPInspire Medical Systems JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$67.00 ➝ $54.005/5/2026INSPInspire Medical Systems Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $65.005/5/2026INSPInspire Medical Systems Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$64.00 ➝ $50.005/5/2026INSPInspire Medical Systems Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$70.00 ➝ $56.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$441.33M2.79$0.79 per share32.15$9.46 per share2.68BBNXBeta Bionics$100.25M4.29N/AN/A$6.09 per share1.58INSPInspire Medical Systems$911.98M1.40$2.78 per share15.91$27.50 per share1.61PLSEPulse Biosciences$350K3,718.96N/AN/A$1.19 per share16.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion$9.77M$0.24105.6926.42N/A2.55%7.21%3.65%N/ABBNXBeta Bionics-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/AINSPInspire Medical Systems$145.42M$4.499.8625.304.7814.33%10.35%8.81%N/APLSEPulse Biosciences-$72.78M-$1.10N/AN/AN/AN/A-80.51%-69.14%N/ALatest BBNX, AORT, INSP, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AORTArtivion$0.06$0.08+$0.02$0.03$115.69 million$116.34 million5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million5/4/2026Q1 2026PLSEPulse Biosciences-$0.32-$0.27+$0.05-$0.27$0.25 million$0.40 million4/21/2026Q1 2026BBNXBeta Bionics-$0.53-$0.49+$0.04-$0.49N/A$27.63 million2/19/2026Q4 2025PLSEPulse Biosciences-$0.32-$0.26+$0.06-$0.26$0.23 millionN/A2/17/2026Q4 2025BBNXBeta Bionics-$0.42-$0.30+$0.12-$0.30N/A$32.12 million2/12/2026Q4 2025AORTArtivion$0.14$0.17+$0.03$0.05$116.42 million$118.30 million2/11/2026Q4 2025INSPInspire Medical Systems$0.69$1.65+$0.96$4.66$264.02 million$269.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/AINSPInspire Medical SystemsN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion0.493.532.62BBNXBeta BionicsN/A10.699.67INSPInspire Medical SystemsN/A6.344.56PLSEPulse BiosciencesN/A10.5310.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%BBNXBeta BionicsN/AINSPInspire Medical Systems94.91%PLSEPulse Biosciences76.95%Insider OwnershipCompanyInsider OwnershipAORTArtivion6.30%BBNXBeta Bionics5.30%INSPInspire Medical Systems2.20%PLSEPulse Biosciences74.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,80048.50 million45.44 millionOptionableBBNXBeta Bionics29444.56 million42.20 millionN/AINSPInspire Medical Systems1,33328.81 million28.18 millionOptionablePLSEPulse Biosciences14068.22 million17.33 millionOptionableBBNX, AORT, INSP, and PLSE HeadlinesRecent News About These CompaniesPulse Biosciences Q1 Earnings Call HighlightsMay 8 at 4:04 PM | marketbeat.comPLSE Q1 2026 Earnings TranscriptMay 8 at 12:12 PM | finance.yahoo.comPulse Biosciences to Present at the BofA Securities 2026 Healthcare ConferenceMay 8 at 12:12 PM | finance.yahoo.comPulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call TranscriptMay 8 at 1:00 AM | seekingalpha.comPulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?May 7 at 1:00 PM | zacks.comPulse Biosciences Reports Business Updates and First Quarter 2026 Financial ResultsMay 4, 2026 | finance.yahoo.comPulse Biosciences (PLSE) Q1 2025 Earnings TranscriptMay 4, 2026 | fool.comPulse Biosciences (NASDAQ:PLSE) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPSMay 4, 2026 | marketbeat.comPulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2026 | zacks.comPulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPulse Biosciences (NASDAQ:PLSE) Shares Down 7.9% - What's Next?April 29, 2026 | marketbeat.comPulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call - SlideshowApril 27, 2026 | seekingalpha.comPulse Biosciences has positive PFA data at HRS 2026April 25, 2026 | massdevice.comPulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call TranscriptApril 25, 2026 | seekingalpha.comPulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026April 25, 2026 | businesswire.comPulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation StoryApril 24, 2026 | finance.yahoo.comPulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation TrialApril 20, 2026 | insidermonkey.comPulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual MeetingApril 20, 2026 | timesargus.comTPulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual MeetingApril 20, 2026 | businesswire.comPulse Biosciences to Host Analyst Event on April 25, 2026April 18, 2026 | finance.yahoo.comPulse Biosciences (NASDAQ:PLSE) Trading 10.1% Higher - Here's WhyApril 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Churchill Downs: The Derby Is Just the BeginningBy Chris Markoch | April 24, 2026BBNX, AORT, INSP, and PLSE Company DescriptionsArtivion NYSE:AORT$25.36 -10.06 (-28.39%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$25.33 -0.03 (-0.13%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Beta Bionics NASDAQ:BBNX$9.65 -0.85 (-8.10%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.64 -0.02 (-0.16%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Inspire Medical Systems NYSE:INSP$44.28 -1.29 (-2.83%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$44.26 -0.02 (-0.05%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Pulse Biosciences NASDAQ:PLSE$19.08 -0.51 (-2.60%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$19.09 +0.01 (+0.05%) As of 05/8/2026 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
